Fasoracetam hydrate | 2055646-53-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Fasoracetam hydrate
• 英文别名: (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one;hydrate
• CAS: 2055646-53-0
• 化学式: C10H18N2O3
• 分子量: 214.26
• InChiKey: YUBYMONBCDIKAB-DDWIOCJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.55
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] SOLID FORMS OF FASORACETAM<br/>[FR] FORMES À L'ÉTAT SOLIDE DE FASORACÉTAM
  申请人：AEVI GENOMIC MEDICINE INC

  公开号：WO2019143824A1

  公开（公告）日：2019-07-25

  The disclosure is directed to cocrystals of fasoracetam, including R-fasoracetam, and various coformers. Crystalline materials comprising fasoracetam, including R-fasoracetam, are also provided. The disclosure further includes pharmaceutical compositions and methods of treatment of the cocrystals and crystalline materials of the disclosure.

  本公开涉及fasoracetam的共晶，包括R-fasoracetam和各种共形物。还提供了包含fasoracetam的结晶材料，包括R-fasoracetam。本公开还包括药物组合物和治疗本公开的共晶和结晶材料的方法。
• NONSELECTIVE METABOTROPIC GLUTAMATE RECEPTOR ACTIVATOR FOR TREATMENT OF 22Q SYNDROME
  申请人：The Children's Hospital Of Philadelphia

  公开号：EP4023222A1

  公开（公告）日：2022-07-06

  This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene.

  本申请涉及用代谢型谷氨酸受体的非选择性激活剂（如法索乙酰胺）治疗注意力缺陷多动障碍（ADHD）、22q缺失和/或重复综合征以及合并症的方法，例如，在至少一个代谢型谷氨酸受体（mGluR）网络基因发生遗传改变的受试者中进行治疗。
• Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome
  申请人：The Children's Hospital of Philadelphia

  公开号：US10869861B2

  公开（公告）日：2020-12-22

  This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mGluR) network gene.

  本申请涉及用代谢型谷氨酸受体的非选择性激活剂（如法索乙酰胺）治疗注意力缺陷多动障碍（ADHD）、22q缺失和/或重复综合征以及合并症的方法，例如，在至少一个代谢型谷氨酸受体（mGluR）网络基因发生遗传改变的受试者中进行治疗。
• Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder
  申请人：THE CHILDREN'S HOSPITAL OF PHILADELPHIA

  公开号：US10918632B2

  公开（公告）日：2021-02-16

  This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).

  本申请涉及用代谢型谷氨酸受体（mGluRs）的非选择性激活剂诊断和治疗神经性厌食症（AN）和暴食症（BED）的方法。
• Methods of diagnosing and treating anxiety disorder
  申请人：THE CHILDREN'S HOSPITAL OF PHILADELPHIA

  公开号：US11173153B2

  公开（公告）日：2021-11-16

  Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

  其中，诊断和治疗可基于对代谢谷氨酸受体（mGluR）网络基因遗传改变的评估，治疗则使用mGluR的非特异性激活剂，如法索乙酰胺。